• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Incorporating Real-World Variability in Clinical IBD Research.

作者信息

Te Velde Anje A

机构信息

Tytgat Institute for Liver and Intestinal Research, Amsterdam UMC location AMC, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM), University of Amsterdam, Amsterdam, The Netherlands.

出版信息

J Eval Clin Pract. 2025 Jun;31(4):e70117. doi: 10.1111/jep.70117.

DOI:10.1111/jep.70117
PMID:40329440
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12056217/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82c9/12056217/2c9f29d8df49/JEP-31-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82c9/12056217/2c9f29d8df49/JEP-31-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82c9/12056217/2c9f29d8df49/JEP-31-0-g001.jpg

相似文献

1
Incorporating Real-World Variability in Clinical IBD Research.在炎症性肠病临床研究中纳入真实世界的变异性
J Eval Clin Pract. 2025 Jun;31(4):e70117. doi: 10.1111/jep.70117.
2
Methodology and Initial Results From a Real-World Observational Cohort of Patients With Inflammatory Bowel Disease: TARGET-IBD.炎症性肠病患者真实世界观察性队列研究的方法与初步结果：TARGET-IBD研究
Crohns Colitis 360. 2021 May 13;3(3):otab023. doi: 10.1093/crocol/otab023. eCollection 2021 Jul.
3
Effectiveness and safety outcomes after long-term (54 weeks) vedolizumab therapy for Crohn's disease: a prospective, real-world observational study including patient-reported outcomes (POLONEZ II).维多珠单抗长期（54周）治疗克罗恩病后的有效性和安全性结果：一项前瞻性、真实世界观察性研究，纳入患者报告结局（POLONEZ II）
Therap Adv Gastroenterol. 2024 Nov 20;17:17562848241293938. doi: 10.1177/17562848241293938. eCollection 2024.
4
Defining predictors of responsiveness to advanced therapies in Crohn's disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicine.定义克罗恩病和溃疡性结肠炎对先进治疗方法反应的预测因素：精准医学中 IBD-RESPONSE 和嵌套 CD-metaRESPONSE 前瞻性、多中心、观察性队列研究的方案。
BMJ Open. 2024 Apr 17;14(4):e073639. doi: 10.1136/bmjopen-2023-073639.
5
Challenges in IBD Research: Pragmatic Clinical Research.炎症性肠病研究面临的挑战：实用临床研究。
Inflamm Bowel Dis. 2019 May 16;25(Suppl 2):S40-S47. doi: 10.1093/ibd/izz085.
6
A real-world longitudinal study implementing digital screening and treatment for distress in inflammatory bowel disease (IBD): The COMPASS-IBD study protocol.一项针对炎症性肠病（IBD）患者痛苦进行数字化筛查和治疗的真实世界纵向研究：COMPASS-IBD 研究方案。
Contemp Clin Trials. 2024 Oct;145:107658. doi: 10.1016/j.cct.2024.107658. Epub 2024 Aug 8.
7
Real-world data on the infliximab biosimilar CT-P13 (Remsima) in inflammatory bowel disease.英夫利昔单抗生物类似药CT-P13（类克）用于炎症性肠病的真实世界数据。
World J Clin Cases. 2021 Dec 26;9(36):11285-11299. doi: 10.12998/wjcc.v9.i36.11285.
8
Use of real-world data to assess the effectiveness of ustekinumab in treating IBD patients: a retrospective linked database study in northwest London.利用真实世界数据评估乌司奴单抗治疗炎症性肠病患者的疗效：伦敦西北部的一项回顾性数据库链接研究。
Expert Opin Biol Ther. 2023 Jul-Dec;23(12):1317-1329. doi: 10.1080/14712598.2023.2279650. Epub 2023 Dec 28.
9
Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective Study.生物疗法和托法替尼对炎症性肠病患者现实工作障碍的影响：一项前瞻性研究。
Inflamm Bowel Dis. 2022 Dec 1;28(12):1813-1820. doi: 10.1093/ibd/izac002.
10
Influence of proton pump inhibitor use on clinical outcomes of patients with inflammatory bowel disease.质子泵抑制剂使用对炎症性肠病患者临床结局的影响。
Ann Med. 2023 Dec;55(1):2198775. doi: 10.1080/07853890.2023.2198775.

本文引用的文献

1
Relative Validity of the Groningen IBD Nutritional Questionnaire (GINQ-FFQ): A Food Frequency Questionnaire Designed to Assess Nutritional Intake in Patients with Inflammatory Bowel Disease.格罗宁根炎症性肠病营养问卷（GINQ-FFQ）的相对效度：一份旨在评估炎症性肠病患者营养摄入情况的食物频率问卷。
Nutrients. 2025 Jan 10;17(2):239. doi: 10.3390/nu17020239.
2
Using Participatory Narrative Inquiry to Assess Experiences and Self-Experimentation with Diet Interventions in Inflammatory Bowel Disease Patients.运用参与式叙事探究法评估炎症性肠病患者饮食干预的经历及自我实验情况。
Nutrients. 2024 Nov 24;16(23):4027. doi: 10.3390/nu16234027.
3
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
mirikizumab治疗中度至重度活动性克罗恩病患者的疗效和安全性：一项3期、多中心、随机、双盲、安慰剂对照和活性对照的持续治疗研究。
Lancet. 2024 Dec 14;404(10470):2423-2436. doi: 10.1016/S0140-6736(24)01762-8. Epub 2024 Nov 21.
4
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial.维多珠单抗预防克罗恩病术后复发（REPREVIO）：一项多中心、双盲、随机、安慰剂对照试验。
Lancet Gastroenterol Hepatol. 2025 Jan;10(1):26-33. doi: 10.1016/S2468-1253(24)00317-0. Epub 2024 Nov 18.
5
The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis.CT-P13 治疗炎症性肠病的疗效：一项系统评价和荟萃分析。
BMC Gastroenterol. 2024 Nov 12;24(1):406. doi: 10.1186/s12876-024-03480-9.
6
An Attack on All Fronts-Extinguishing the Fire of IBD with an Integrative Approach.全面出击——采用综合方法扑灭炎症性肠病之火
Dig Dis Sci. 2025 Feb;70(2):451-453. doi: 10.1007/s10620-024-08642-z. Epub 2024 Oct 24.
7
Assessment of outcomes in Crohn's disease: A systematic review of randomized clinical trials to inform a multiple outcome framework.评估克罗恩病的结局：一项系统评价随机临床试验，为多结局框架提供信息。
United European Gastroenterol J. 2024 Nov;12(9):1280-1291. doi: 10.1002/ueg2.12679. Epub 2024 Oct 11.
8
Noninvasive, microbiome-based diagnosis of inflammatory bowel disease.基于微生物群的炎症性肠病无创诊断
Nat Med. 2024 Dec;30(12):3555-3567. doi: 10.1038/s41591-024-03280-4. Epub 2024 Oct 4.
9
Every problem is embedded in a greater whole.每个问题都嵌入在更大的整体中。
J Eval Clin Pract. 2025 Feb;31(1):e14139. doi: 10.1111/jep.14139. Epub 2024 Sep 23.
10
A Comprehensive Review of the Triangular Relationship among Diet-Gut Microbiota-Inflammation.饮食-肠道微生物群-炎症的三角关系综述
Int J Mol Sci. 2024 Aug 29;25(17):9366. doi: 10.3390/ijms25179366.